Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O. Box 22, FIN-90029, Oulu, Finland.
Department of Pathology, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
BMC Cancer. 2017 Jan 24;17(1):72. doi: 10.1186/s12885-017-3056-4.
Breast carcinomas with neuroendocrine features (NEBC) are a very rare entity of mammary neoplasms, WHO classification of which has recently been revised. There are very limited data available about the clinical behaviour and treatment options of NEBC.
We collected retrospectively patients with NEBC from Oulu and Helsinki University Hospitals in 2007-2015. There were 43 NEBC cases during the period.
The incidence of NEBC from all breast cancers varied from 0.1% in Helsinki to 1.3% in Oulu. The mean tumor size was 2.2 cm and 23 patients (55.8%) had no lymph node metastases when diagnosed. In total, 4 patients (9.3%) had distant metastases at the time of diagnosis. High estrogen receptor (ER) expression was observed in 41 (97.7%) patients. When non-metastatic NEBC were compared to a prospective set of ductal carcinomas (n = 506), NEBC were more often HER2 negative (p = 0.046), ER positive (p = 0.0062) and the NEBC patients were older (p < 0.0005) than patients with ductal carcinomas. Plasma chromogranin A correlated only to higher age at diagnosis (p = 0.0028). Relapse-free survival (p = 0.0013), disease-free survival (p = 0.024) and overall survival (p = 0.0028) favoured ductal carcinomas compared to NEBC, while no difference was observed in distant disease-free survival or in breast cancer-specific survival.
There is remarkable variation in the incidence of NEBC in Finland, which is likely to be explained by differences in the use of neuroendocrine marker immunostainings. Poor local control and worse overall survival may be linked to the more aggressive biology of the disease, despite its association with apparently indolent prognostic factors.
具有神经内分泌特征的乳腺癌(NEBC)是一种非常罕见的乳腺肿瘤实体,最近对其进行了 WHO 分类修订。关于 NEBC 的临床行为和治疗选择的可用数据非常有限。
我们回顾性地收集了 2007 年至 2015 年在奥卢和赫尔辛基大学医院就诊的 NEBC 患者。在此期间,共有 43 例 NEBC 病例。
从所有乳腺癌来看,NEBC 的发病率在赫尔辛基为 0.1%,在奥卢为 1.3%。平均肿瘤大小为 2.2 厘米,23 名患者(55.8%)在诊断时无淋巴结转移。共有 4 名患者(9.3%)在诊断时存在远处转移。41 名患者(97.7%)存在高雌激素受体(ER)表达。与前瞻性的导管癌组(n=506)相比,非转移性 NEBC 更常为 HER2 阴性(p=0.046),ER 阳性(p=0.0062),且 NEBC 患者年龄更大(p<0.0005)。血浆嗜铬粒蛋白 A 仅与诊断时的年龄较高相关(p=0.0028)。无复发生存率(p=0.0013)、无病生存率(p=0.024)和总生存率(p=0.0028)有利于导管癌,而远处无病生存率或乳腺癌特异性生存率则无差异。
芬兰的 NEBC 发病率存在显著差异,这很可能是由于神经内分泌标志物免疫染色的使用差异所致。尽管与明显惰性的预后因素相关,但较差的局部控制和较差的总体生存率可能与疾病的侵袭性生物学有关。